Stephen Liu: TKI-Based Induction Therapy Enables Surgery in Initially Unresectable EGFR-Mutant NSCLC

Stephen Liu, Chief of Division of Hematology and Oncology at Georgetown Lombardi Comprehensive Cancer Center, shared on X:

“Report describes 162 consecutive patients with initially unresectable EGFR+ NSCLC (stage IIIA-N2b to IIIC) treated with TKI-based induction.

• 70/162 felt converted to resectable
• 42 underwent resection.

MPR rate 31%, 1 pCR, 60% LN downstaged.”

Title: Conversion Surgery After EGFR-TKI Induction for Initially Unresectable EGFR-Mutant Stage III NSCLC

Authors: Yu Jiang, Yuechun Lin, Peiling Chen, Wenhai Fu, Hongsheng Deng, Ying Huang, Runchen Wang, Jianqi Zheng, Sangtian Liu, Jingpei Li, Wei Wang, Hengrui Liang, Jianxing He, Wenhua Liang

Read the full article.

You can also read:

Unresectable Stage III NSCLC: PACIFIC Remains the Backbone as Precision Strategies Reshape Care